Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jiagui Qu"'
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e89989 (2014)
Selective attention has traditionally been viewed as a sensory processing modulator that promotes cognitive processing efficiency by favoring relevant stimuli while inhibiting irrelevant stimuli. However, the cross-modal processing of irrelevant info
Externí odkaz:
https://doaj.org/article/8c056ffd68fd446e87b872a70a48d49b
Publikováno v:
Biocell. 2022, Vol. 46 Issue 3, p1041-1051. 11p.
Autor:
Guizhong Liu, Zhengxi Dai, Jiagui Qu, Jianfeng Shi, Qi Zhao, Linhai Qu, Yan Li, Songmao Zheng, Jiangchun Xu, Felix Du, Peter Luo
Publikováno v:
Cancer Research. 82:2868-2868
Targeting CD137 by agonistic antibodies faces various challenges in the clinic. Utomilumab appears safe but has modest efficacy, while urelumab is more efficacious but causes severe dose-dependent liver toxicity. To unlock the full potential of CD137
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc9155c0b212a60f20a69bc5f73e2ae9
https://doi.org/10.1158/1538-7445.am2022-2868
https://doi.org/10.1158/1538-7445.am2022-2868
Autor:
Guizhong Liu, Zhengxi Dai, Jiagui Qu, Jianfeng Shi, Qi Zhao, Bin Cai, Aaron N. Nguyen, Songmao Zheng, Jiangchun Xu, Yan Li, Felix Du, Peter Luo
Publikováno v:
Cancer Research. 82:2888-2888
Targeting CD28 for systemic T cell activation caused severe cytokine storm and multiorgan failure in an anti-CD28 antibody TGN1412 phase 1 trial. However, tumor specific CD28 targeting in a tumor associated antigen (TAA)×CD28 bispecific format, simi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af9e05fd14f8808636aab233c1177071
https://doi.org/10.1158/1538-7445.am2022-2888
https://doi.org/10.1158/1538-7445.am2022-2888
Autor:
Guizhong Liu, Yan Li, Zhengxi Dai, Jiagui Qu, Jianfeng Shi, Qi Zhao, Linhai Qu, Aaron N. Nguyen, Songmao Zheng, Jiangchun Xu, Felix Du, Peter Luo
Publikováno v:
Cancer Research. 82:2869-2869
Bispecific T-cell engagers (TCEs) have shown therapeutic promise in treating hematologic cancers. However, their utility in treating solid tumors has yet to be effectively demonstrated due to on-target off-tumor toxicity and systemic cytokine release
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1064a14926e315a16ec2b8555af8a8c6
https://doi.org/10.1158/1538-7445.am2022-2869
https://doi.org/10.1158/1538-7445.am2022-2869
Autor:
Hua Niu, Zhuxian Ping, Jiagui Qu, Mark Perfetto, Xiangcai Yang, Yu Shi, Shuting Mei, Shuo Wei, Jiejing Li, Qin Zhang, Laura Christian
Publikováno v:
Scientific Reports
Malignant glioma is a formidable disease that commonly leads to death, mainly due to the invasion of tumor cells into neighboring tissues. Therefore, inhibition of tumor cell invasion may provide an effective therapy for malignant glioma. Here we rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1bc79aad8055ebdd7046ace3fc47ab6
Autor:
Likun Zhang, Gavin Jiagui Qu, Jie Cai, Davy Xuesong Ouyang, Henry Q. X. Li, Li Chen, Annie Xiaoyu An
Publikováno v:
Cancer Research. 77:2807-2807
Recent success of multiple poly (adenosine diphosphate [ADP]) ribose polymerase inhibitors (PARPi) in treating BRCA mutant ovarian cancers has fueled the development of PARPi in several areas, including expanding its use in other BRCA mutant or wildt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eff7a438d57d8846365dcfbee34eaccc
https://doi.org/10.1158/1538-7445.am2017-2807
https://doi.org/10.1158/1538-7445.am2017-2807
Publikováno v:
Human cell. 27(3)
This paper outlines the establishment of a new and stable cell line, designated GBM-HSF, from a malignant glioblastoma multiforme (GBM) removed from a 65-year-old Chinese woman. This cell line has been grown for 1 year without disruption and has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1e704c15aa066878d3bb97c00893dfd
https://pubmed.ncbi.nlm.nih.gov/24390806
https://pubmed.ncbi.nlm.nih.gov/24390806
Publikováno v:
Cancer Immunology Research. 4:B137-B137
Lack of relevant animal model is a major bottleneck for developing novel immunotherapy. The current workhorse is syngeneic mouse tumor model where mouse cancer cell lines were engrafted in syngeneic mice. However, these models suffer from several lim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3da78e09c2f09791fcf19c2894b2a6d7
https://doi.org/10.1158/2326-6066.imm2016-b137
https://doi.org/10.1158/2326-6066.imm2016-b137
Autor:
Jinping Liu, Zhun Wang, Jie Cai, Likun Zhang, Jiagui Qu, Xiaoyu An, Henry Li, Jean-Pierre Wery, Xuesong Ouyang
Publikováno v:
Cancer Research. 76:3219-3219
We previously generated the MuPrime® mBR6004 model, by engrafting the breast adenocarcinoma derived from MMTV-PyVT transgenic mice (GEMM)1 into the syngeneic FVB/N mice2,3. The allograft grows robustly, maintains the histopathology features of the o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::460c98074dfcd08ea9924d69250d523c
https://doi.org/10.1158/1538-7445.am2016-3219
https://doi.org/10.1158/1538-7445.am2016-3219